CD274 and neoplasm: Aligning with findings in other tumor types, the PD-L1 positivity cut point to achieve clinical benefit is indeed tumor-dependent; for example, non-small cell lung cancer utilizes a TPS ≥ 1%, whereas in advanced triple-negative breast cancer clinical benefit is demonstrated for patients with a combined positive score (CPS) ≥ 10.